Showing 651-660 of 2150 results for "".
- Remembering Ronald DeVere, MD, FAANhttps://practicalneurology.com/news/remembering-ronald-devere-md-faan/2470936/Ronald DeVere, MD, FAAN, Practical Neurology Editorial Advisory Board member and former Editor of the Dementia Insights column, passed away on May 8, 2024, at age 80. Dr. DeVere served as the Director of the Taste & Smell Disorders Clinic and the Alzheimer Disease & Memory Disorder
- New Insights into ARIA-E Risk from Donanemab Studieshttps://practicalneurology.com/news/new-insights-into-aria-e-risk-from-donanemab-studies/2470464/In an effort to understand more about amyloid-related imaging abnormalities (ARIA) associated with anti-amyloid therapy, researchers analyzed pooled data from 3 studies involving donanemab (Eli Lilly and Company, Indianapolis, IN) therapy for individuals with early Alzheimer disease (AD):
- Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkinshttps://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
- In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANAhttps://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
- 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research Presented to Lars Lannfelt, MD, PhDhttps://practicalneurology.com/news/2024-lifetime-achievement-award-in-alzheimers-disease-therapeutic-research-presented-to-lars-lannfelt-md-phd/2470618/Lars Lannfelt, MD, PhD has been recognized as the recipient of the 2024 Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference. Dr. Lannfelt was selected based on his pioneering work in Alzheim
- UCSF Professor Bruce Ovbiagele, MD Recognized with Scientific Breakthrough Award at AAN 2024https://practicalneurology.com/news/ucsf-professor-bruce-ovbiagele-md-recognized-with-scientific-breakthrough-award-at-aan-2024/2470442/This year, the American Brain Foundation (ABF) awarded Bruce Ovbiagele, MD, MAS, FAAN the annual Scientific Breakthrough Award. Dr Ovbiagele, a Professor of Neurology at University of California (UC) San Francisco and Associate Dean of the San Francisco Veterans Affairs (VA) Healthcare Syste
- Enhanced Kisunla Dosing Regimen Reduced ARIA-E Risk While Maintaining Amyloid Reduction in Early Alzheimer Diseasehttps://practicalneurology.com/news/enhanced-kisunla-dosing-regimen-reduces-aria-e-risk-while-maintaining-amyloid-reduction-in-early-alzheimer-disease/2470624/Results from the multicenter, randomized, double-blind, phase 3b TRAILBLAZER-ALZ 6 (NCT05738486) clinical trial revealed that an enhanced dosing regimen for Kisunla (donanemab; Eli Lilly and Company, Indianapolis, IN) significantly reduces the frequency and severity of amyloid-related imaging abn
- Evrysdi Therapy for Type 1 Spinal Muscular Atrophy Associated with Favorable 5-Year S&E Datahttps://practicalneurology.com/news/evrysdi-therapy-for-type-1-spinal-muscular-atrophy-associated-with-favorable-5-year-se-data/2470501/Five-year data from the open-label extension of the phase 2 FIREFISH (NCT02913482) clinical trial confirms the sustained efficacy and safety profile of Evrysdi (ridisplam; Genentech, South San Francisco, CA), a treatment for children with Type 1 spinal muscular atrophy (SMA). The results demonstr
- Subcutaneous Lecanemab Shown to Have Similar Efficacy to IV Lecanemab and May Reduce ARIA-Ehttps://practicalneurology.com/news/subcutaneous-lecanemab-shown-to-have-similar-efficacy-to-iv-lecanemab-and-may-reduce-aria-e/2470249/Subcutaneous injection of lecanemab (Eisai, Tokyo, Japan; Biogen, Cambridge, MA) using a vial or autoinjector yielded comparable average steady-state concentrations (Css) to intravenous (IV) administration o
- Oral Edaravone Well-Tolerated as ALS Therapyhttps://practicalneurology.com/news/oral-edaravone-well-tolerated-as-als-therapy/2470134/Oral e